Cilostazol in patients with ischemic stroke

被引：7

作者：

Al-Qudah, Zaid A. ^{[1
]}

Hassan, Ameer E. ^{[1
]}

Qureshi, Adnan I. ^{[1
]}

机构：

[1] Univ Minnesota, Zeenat Qureshi Stroke Res Ctr, Dept Neurol, Minneapolis, MN 55455 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 08期

关键词：

acute ischemic stroke; cilostazol; neurointerventional procedures; FOCAL CEREBRAL-ISCHEMIA; DOUBLE-BLIND; TRIAL; ASPIRIN; DAMAGE; TICLOPIDINE; CLOPIDOGREL; ADENOSINE; EVENTS; RISK;

D O I：

10.1517/14656566.2011.576248

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Several antiplatelets have been used in the prevention of secondary ischemic strokes with limited success and some carried a high risk of bleeding. Cilostazol is a relatively new antiplatelet that has been thoroughly investigated in Japan with promising outcome in secondary stroke prevention. Areas covered: In this paper, the findings of major clinical trials and the efficacy of cilostazol in preventing ischemic stroke in comparison with other more commonly used antiplatelet medications like aspirin and clopidogrel are summarized. Pharmacology and mechanism of action are also discussed. Expert opinion: Cilostazol is a safe and effective medication. It has an antiplatelet, antithrombotic and vascular endothelial proliferation inhibitory effect that makes it an excellent, promising drug for the prevention of secondary ischemic stroke and poststent thrombosis.

引用

页码：1305 / 1315

页数：11

共 29 条

[1]

[Anonymous], NME DRUG NEW BIOL AP

[2]

Cojocaru Inimoara Mihaela, 2010, Rom J Intern Med, V48, P101

[3] RACTS: A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting long-term clinical and angiographic outcome - Long-term clinical and angiographic outcome [J].

Ge, JB ;

Han, YL ;

Jiang, H ;

Sun, BG ;

Chen, JY ;

Zhang, SY ;

Du, ZM .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 46 (02) :162-166

[4] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].

Gent, M ;

Beaumont, D ;

Blanchard, J ;

Bousser, MG ;

Coffman, J ;

Easton, JD ;

Hampton, JR ;

Harker, LA ;

Janzon, L ;

Kusmierek, JJE ;

Panak, E ;

Roberts, RS ;

Shannon, JS ;

Sicurella, J ;

Tognoni, G ;

Topol, EJ ;

Verstraete, M ;

Warlow, C .

LANCET, 1996, 348 (9038) :1329-1339

[5] Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding [J].

Goto, Shinya .

ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (04) :3-11

[6]

GOTOH HTF, 2000, J STROKE CEREBROVASC, V9, P147

[7] Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study [J].

Han, Yaling ;

Li, Yi ;

Wang, Shouli ;

Jing, Quanmin ;

Wang, Zhulu ;

Wang, Dongmei ;

Shu, Qingfen ;

Tang, Xiuying .

AMERICAN HEART JOURNAL, 2009, 157 (04) :733-739

[8] Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events [J].

Hankey, Graeme J. ;

Eikelboom, John W. .

LANCET NEUROLOGY, 2010, 9 (03) :273-284

[9] A RANDOMIZED TRIAL COMPARING TICLOPIDINE HYDROCHLORIDE WITH ASPIRIN FOR THE PREVENTION OF STROKE IN HIGH-RISK PATIENTS [J].

HASS, WK ;

EASTON, JD ;

ADAMS, HP ;

PRYSEPHILLIPS, W ;

MOLONY, BA ;

ANDERSON, S ;

KAMM, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (08) :501-507

[10] Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol [J].

Hiratsuka, Masahiro ;

Hinai, Yudai ;

Sasaki, Takamitsu ;

Konno, Yumiko ;

Imagawa, Kenichi ;

Ishikawa, Masaaki ;

Mizugaki, Michinao .

DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) :1730-1732

← 1 2 3 →